Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of bimekizumab in psoriatic arthritis
2018-004725-86Phase 3Active
- Sponsor
- UCB
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bimekizumab in psoriatic arthritis (PsA), sponsored by UCB. Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs). Started Aug 2019; status: active.
02
Drugs
bimekizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2018-004725-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004725-86.